277 related articles for article (PubMed ID: 19139031)
1. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking.
Luque-Ramírez M; Mendieta-Azcona C; del Rey Sánchez JM; Matíes M; Escobar-Morreale HF
Eur J Endocrinol; 2009 Mar; 160(3):469-80. PubMed ID: 19139031
[TBL] [Abstract][Full Text] [Related]
2. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF
J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
[TBL] [Abstract][Full Text] [Related]
3. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome.
Rautio K; Tapanainen JS; Ruokonen A; Morin-Papunen LC
Eur J Endocrinol; 2005 Feb; 152(2):269-75. PubMed ID: 15745936
[TBL] [Abstract][Full Text] [Related]
4. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
Luque-Ramírez M; Alvarez-Blasco F; Uriol Rivera MG; Escobar-Morreale HF
Hum Reprod; 2008 Jul; 23(7):1594-601. PubMed ID: 18375410
[TBL] [Abstract][Full Text] [Related]
5. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
6. [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].
Orbetsova M; Kamenov Z; Kolarov G; Zakharieva S; Khristov V; Atanasova I; Shigarminova R; Milcheva B; Genchev G
Akush Ginekol (Sofiia); 2006; 45(7):16-28. PubMed ID: 17489164
[TBL] [Abstract][Full Text] [Related]
7. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin.
Feng W; Jia YY; Zhang DY; Shi HR
Gynecol Endocrinol; 2016; 32(2):147-50. PubMed ID: 26507097
[TBL] [Abstract][Full Text] [Related]
8. Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome.
Luque-Ramírez M; Mendieta-Azcona C; Alvarez-Blasco F; Escobar-Morreale HF
Fertil Steril; 2009 Jun; 91(6):2527-36. PubMed ID: 18565522
[TBL] [Abstract][Full Text] [Related]
9. Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients.
Kebapcilar L; Kebapcilar AG; Bilgir O; Taner CE; Bozkaya G; Yildiz Y; Sari I
Gynecol Endocrinol; 2011 Feb; 27(2):91-5. PubMed ID: 20528207
[TBL] [Abstract][Full Text] [Related]
10. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):209-13. PubMed ID: 15653205
[TBL] [Abstract][Full Text] [Related]
11. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
[TBL] [Abstract][Full Text] [Related]
12. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Sanchón R; San Millán JL; Escobar-Morreale HF
Diabetes Care; 2007 Sep; 30(9):2309-13. PubMed ID: 17536071
[TBL] [Abstract][Full Text] [Related]
13. Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes.
Wu H; Ruan X; Jin J; Mueck AO
Gynecol Endocrinol; 2015 Jul; 31(7):548-51. PubMed ID: 26004979
[TBL] [Abstract][Full Text] [Related]
14. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
[TBL] [Abstract][Full Text] [Related]
15. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome.
Morin-Papunen L; Rautio K; Ruokonen A; Hedberg P; Puukka M; Tapanainen JS
J Clin Endocrinol Metab; 2003 Oct; 88(10):4649-54. PubMed ID: 14557435
[TBL] [Abstract][Full Text] [Related]
16. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
[TBL] [Abstract][Full Text] [Related]
17. Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate.
Markantes G; Saltamavros AD; Vervita V; Armeni AK; Karela A; Adonakis G; Decavalas G; Georgopoulos NA
Gynecol Endocrinol; 2011 Dec; 27(12):971-7. PubMed ID: 21501001
[TBL] [Abstract][Full Text] [Related]
18. How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?
Kabil Kucur S; Gozukara I; Aksoy A; Uludag EU; Keskin H; Kamalak Z; Carlioglu A
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):862-5. PubMed ID: 25402193
[TBL] [Abstract][Full Text] [Related]
19. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome.
Kebapcilar L; Taner CE; Kebapcilar AG; Alacacioglu A; Sari I
Arch Gynecol Obstet; 2010 Jan; 281(1):35-42. PubMed ID: 19330342
[TBL] [Abstract][Full Text] [Related]
20. Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.
Ibáñez L; De Zegher F
Hum Reprod; 2004 Aug; 19(8):1725-7. PubMed ID: 15229206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
